Thirty Days of an Oral Simvastatin Intervention Does Not Change Nitric Oxide-Mediated Micro- and Macrovascular Endothelial Function in Women with Endometriosis

In: Physiology · 2025 · vol. 40(S1) · doi:10.1152/physiol.2025.40.s1.0341 · W4411847271
article OA: closed CC0
Full text JSON View on OpenAlex View at publisher
AI-generated summary by claude@2026-06, 2026-06-08

Thirty days of oral simvastatin did not alter nitric oxide-mediated micro- and macrovascular endothelial function in women with endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Purpose: Endometriosis is characterized by the presence of endometrium-like tissue outside the uterine cavity. This estrogen-dependent disease is associated with systemic inflammation and increased risk of cardiovascular disease. In primate models of endometriosis, systemic treatment with simvastatin reduces endometrial lesion load. Seven days of atorvastatin improves nitric oxide (NO)-mediated endothelial function in women with endometriosis, but the impact of a longer intervention with simvastatin that specifically targets endometriosis-associated inflammation has yet to be investigated. We hypothesized a thirty-day oral simvastatin intervention would improve NO-mediated micro- and macrovascular endothelial function in women with endometriosis. Methods: In seven women with laparoscopically confirmed endometriosis, cutaneous microvascular function and brachial artery flow-mediated dilation (FMD) were measured at baseline and following a thirty-day simvastatin intervention (10mg/day). In a subset of five women, FMD+Handgrip (HG) was also measured before and after the intervention. Two intradermal microdialysis fibers were placed into the ventral forearm skin. Laser-Doppler flowmetry was used to measure cutaneous blood flow while increasing concentrations of acetylcholine (10 -10 to 10 -1 M; endothelium-dependent vasodilator) were perfused with a control (lactated Ringer’s; CTL) or a non-specific NO synthase inhibitor (15 mM N G -nitro-L-arginine methyl ester; L-NAME) set to a thermoneutral 33 °C. Following the dose-response protocol, maximal cutaneous vasodilation was induced by increasing local skin temperature to 43 °C and perfusing 28 mM sodium nitroprusside. Cutaneous vascular conductance (CVC) was calculated as the quotient of red blood cell flux over mean arterial pressure and normalized as a percentage of the site-specific maximum (CVC %max ). Area under the dose-response curve (AUC) of the CTL and L-NAME sites were calculated using the trapezoid rule. FMD and FMD+HG are expressed as the percent change in brachial artery diameter in response to post-occlusive reactive hyperemia (PORH) and PORH+HG at 20% maximum voluntary contraction relative to baseline, respectively. FMD baseline diameter was continuously measured for 2 min, cuff occlusion for 5 min, and post-occlusion for 4 min, where FMD+HG was a 3 min cuff occlusion with HG (GE Logiq E). Edge detection software (Cardiovascular Suite 4) was utilized. Results: In the cutaneous microcirculation, there was no main effect of simvastatin treatment ( p =0.46) or localized NO synthase inhibition ( p =0.55) following a thirty-day simvastatin treatment [Mean (SD): Baseline - CTL: 273 (121) vs. L-NAME: 191 (109); Simvastatin - CTL: 251 (102) vs. L-NAME: 279 (131) AU]. Simvastatin treatment also did not alter %FMD [Baseline: 4.73 (2.96)% vs. Simvastatin: 5.50 (2.99)%; p =0.61] and %FMD+HG [Baseline: 8.65 (3.75)% vs. Simvastatin: 9.48 (4.56)%; p =0.66] in women with endometriosis. Conclusion: Thirty-days of an oral simvastatin intervention did not alter NO-mediated micro- and macrovascular endothelial function in women with endometriosis. The data suggest that the duration, dose, and class of statin is important for targeting peripheral vascular function in women with endometriosis. Diversity Supplement R01 HL161000-02S2 (VGC), NIH F31 HL170616-0 (ACW), NIH Grant R01 HL161000 (NSS, LMA) This abstract was presented at the American Physiology Summit 2025 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.
Full text 4,818 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Purpose: Endometriosis is characterized by the presence of endometrium-like tissue outside the uterine cavity. This estrogen-dependent disease is associated with systemic inflammation and increased risk of cardiovascular disease. In primate models of endometriosis, systemic treatment with simvastatin reduces endometrial lesion load. Seven days of atorvastatin improves nitric oxide (NO)-mediated endothelial function in women with endometriosis, but the impact of a longer intervention with simvastatin that specifically targets endometriosis-associated inflammation has yet to be investigated. We hypothesized a thirty-day oral simvastatin intervention would improve NO-mediated micro- and macrovascular endothelial function in women with endometriosis. Methods: In seven women with laparoscopically confirmed endometriosis, cutaneous microvascular function and brachial artery flow-mediated dilation (FMD) were measured at baseline and following a thirty-day simvastatin intervention (10mg/day). In a subset of five women, FMD+Handgrip (HG) was also measured before and after the intervention. Two intradermal microdialysis fibers were placed into the ventral forearm skin. Laser-Doppler flowmetry was used to measure cutaneous blood flow while increasing concentrations of acetylcholine (10-10 to 10-1 M; endothelium-dependent vasodilator) were perfused with a control (lactated Ringer’s; CTL) or a non-specific NO synthase inhibitor (15 mM N G-nitro-L-arginine methyl ester; L-NAME) set to a thermoneutral 33 °C. Following the dose-response protocol, maximal cutaneous vasodilation was induced by increasing local skin temperature to 43 °C and perfusing 28 mM sodium nitroprusside. Cutaneous vascular conductance (CVC) was calculated as the quotient of red blood cell flux over mean arterial pressure and normalized as a percentage of the site-specific maximum (CVC%max). Area under the dose-response curve (AUC) of the CTL and L-NAME sites were calculated using the trapezoid rule. FMD and FMD+HG are expressed as the percent change in brachial artery diameter in response to post-occlusive reactive hyperemia (PORH) and PORH+HG at 20% maximum voluntary contraction relative to baseline, respectively. FMD baseline diameter was continuously measured for 2 min, cuff occlusion for 5 min, and post-occlusion for 4 min, where FMD+HG was a 3 min cuff occlusion with HG (GE Logiq E). Edge detection software (Cardiovascular Suite 4) was utilized. Results: In the cutaneous microcirculation, there was no main effect of simvastatin treatment (p =0.46) or localized NO synthase inhibition (p =0.55) following a thirty-day simvastatin treatment [Mean (SD): Baseline - CTL: 273 (121) vs. L-NAME: 191 (109); Simvastatin - CTL: 251 (102) vs. L-NAME: 279 (131) AU]. Simvastatin treatment also did not alter %FMD [Baseline: 4.73 (2.96)% vs. Simvastatin: 5.50 (2.99)%; p =0.61] and %FMD+HG [Baseline: 8.65 (3.75)% vs. Simvastatin: 9.48 (4.56)%; p =0.66] in women with endometriosis. Conclusion: Thirty-days of an oral simvastatin intervention did not alter NO-mediated micro- and macrovascular endothelial function in women with endometriosis. The data suggest that the duration, dose, and class of statin is important for targeting peripheral vascular function in women with endometriosis. Diversity Supplement R01 HL161000-02S2 (VGC), NIH F31 HL170616-0 (ACW), NIH Grant R01 HL161000 (NSS, LMA) This abstract was presented at the American Physiology Summit 2025 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process. Information & Authors Information Published In Physiology Volume 40 • Issue S1 • May 2025 Copyright Copyright © 2025 Int. Union Physiol. Sci./Am. Physiol. Soc. History Published in print: May 2025 Published online: 12 May 2025

Keyword

Authors Metrics & Citations Metrics Article Usage - For recently published articles, the total views count will show as 0 until a new month begins. - There is a 3–4 day delay in usage data reporting after article publication. - Citation counts are from the Crossref Cited-by service. Altmetrics Dimensions Scite Citations If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click on download. Download article citation data for: Physiology 2025 40:S1 Physiology 2025 40:S1 View Options View options Access content To read the fulltext, please use one of the options below to sign in or purchase access. This functionality works only for purchases made as a guest

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK